Skip to main content
main-content

10.10.2017 | Onkologie | Onlineartikel

Reaching unprecedented outcome dimensions in malignant

Autor:
Judith Moser
Malignant pleural mesothelioma (MPM) is a rare but aggressive cancer with poor prognosis. While combination chemotherapy with platinum and pemetrexed with or without bevacizumab is a standard in first-line treatment, no approved second-line strategies have been established to date [1]. Read more ...

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten